GlassScriptPhysician profile
Linda K Oge
NPI 1801894217
$932.10
in general payments reported to CMS, 2019-2025
20 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.73 · 2021: $46.90 · 2022: $320 · 2023: $86.67 · 2024: $255 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $156.45 | 2022 | |
| Amgen INC. | $136.38 | 2024-2025 | Tezspire |
| Pfizer INC. | $75.56 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $60.81 | 2019-2022 | |
| Glaxosmithkline, LLC. | $56.23 | 2019-2025 | Shingrix, Arexvy |
| Dexcom, INC. | $52.55 | 2022-2025 | Dexcom G6 Transmitter |
| Organon LLC | $49.93 | 2021-2025 | Nexplanon |
| Janssen Pharmaceuticals, INC | $42.20 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $41.72 | 2023-2024 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $38.62 | 2025 | Tremfya, Simponi Aria |
| Mylan Specialty L.P. | $38.30 | 2024 | Yupelri |
| Global Blood Therapeutics, INC. | $36.71 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $24.28 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.46 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $23.25 | 2024 | Crysvita |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $18.77 | 2025 | Immunocap |
| Lilly USA, LLC | $16.98 | 2023 | Mounjaro |
| Abbott Laboratories | $16.73 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $11.97 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $11.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Oge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.